Technology | August 01, 2014

Sorin Group Announces FDA Approval of Solo Smart — the Next Evolution in Tissue Valve Technology

Solo Smart is the first aortic valve with a removable stent, providing native-like performance with the ease of implant of a stented valve

Sorin Group Solo Smart Heart Valve Repair

August 1, 2014 — Sorin Group received U.S. Food and Drug Administration (FDA) approval for the Solo Smart Aortic Pericardial Heart Valve.

Solo Smart is the first valve with a removable stent to be approved in the U.S. market. Designed from bovine pericardium, the valve is fully biological with no synthetic material added. This unique bioprosthesis mimics the healthy native aortic valve in order to preserve the aortic root physiology. By perfectly aligning to the patient’s annulus with a 100 percent orifice-to-annulus ratio, Solo Smart maximizes blood flow and delivers excellent hemodynamic performance.

The removable Ni-Ti alloy stent sets Solo Smart apart from all other valves, as this unique feature provides support during implantation and is then completely removed. The removable stent along with the single-suture line implant technique reduces the time spent seating and suturing the valve. The prosthesis is treated for the elimination of aldehyde residuals so it is not necessary to rinse the valve before implantation. Once the stent is removed following implantation, Solo Smart becomes an entirely stentless valve, providing low pressure gradients and large orifice areas.[1]

Solo Smart is the evolution of the Freedom Solo valve, which has been implanted in international markets since 2004. This valve has been evaluated in numerous clinical studies representing over 4,000 patients with follow-up to eight years.

“I am very excited to begin implanting the Solo Smart valve, said David Heimansohn, M.D., St. Vincent Heart Center, Indianapolis, who participated in the U.S. IDE clinical study. “Solo Smart is the closest bioprosthesis to the native aortic valve and allows me to offer my patients a solution that provides superior hemodynamics while reducing the length of surgery.”

For more information: www.sorin.com

References:

1. A. Repossini, M. Rambaldini, V. Lucchetti, U. Da Col, F. Cesari, C. Mignosa, E. Picano and M. Glauber; Eur J Cardiothorac Surg. 2012;41(5):1104-111.

 

 

 

Related Content

TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform
News | Heart Valve Technology | February 18, 2019
Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE)...
Thubrikar Announces First-in-Human Implant of Optimum TAVI System
News | Heart Valve Technology | January 29, 2019
Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve...
Perceval Valve Offers Performance, Economic Advantages in Aortic Disease Treatment
News | Heart Valve Technology | January 29, 2019
LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic...
First Tendyne Transcatheter Mitral Valve Implanted in New York
News | Heart Valve Technology | January 28, 2019
Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...
Overlay Init